COVID-19 vaccination - summary for immunisation providers
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COVID-19 vaccination – summary for immunisation providers 23 February 2022 The Australian Government Department of Health website now has a dedicated page for Clinical guidance for COVID-19 vaccine providers. This page has the latest updates from the Australian Technical Advisory Group on Immunisation (ATAGI), clinical information, COVID-19 vaccines doses and recommendations, vaccine efficacy and effectiveness, and additional clinical considerations. We have provided some additional relevant information below. Contents Latest advice Myocarditis and pericarditis COVID-19 vaccine safety surveillance Variants of concern Vaccine ingredients Answering patients questions and concerns about COVID-19 vaccines Case numbers and statistics Other resources COVID-19 vaccination: summary for immunisation providers | 23 February 2022 1
Latest advice – as at 23 February 2022
ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children
aged 6 to 11 years
The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for the
use of the Moderna COVID-19 vaccine in children aged 6 to 11 years.
Related resource:
ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11
years
Recommendations on the use of Comirnaty (Pfizer) in adolescents aged 16 to 17 years
Recommendations on the use of Comirnaty (Pfizer) in adolescents aged 16 to 17 years have been included
in the Clinical recommendations for COVID-19 vaccines and resources.
Related resources:
Clinical recommendations for COVID-19 vaccines
COVID-19 vaccine information
Information on the use of Nuvaxovid (Novavax) COVID-19 vaccine
Information on the use of Nuvaxovid – the Novavax COVID-19 vaccine has been incorporated into the
Clinical recommendations for COVID-19 vaccines and resources.
Related resources:
Clinical recommendations for COVID-19 vaccines
COVID-19 vaccine doses and administration
COVID-19 vaccine contraindications and precautions
COVID-19 vaccine adverse events
Recommendations on the timing of booster doses following the primary course
Recommendations on the timing of booster doses following the primary course have been updated from 4
months to 3 months.
Related resource: Booster dose recommendations
Myocarditis and pericarditis
There is a link between mRNA COVID-19 vaccines – such as Comirnaty (Pfizer) and Spikevax (Moderna) – and rare
side effects of myocarditis and pericarditis. These are reported to be seen more commonly in males under 30 years of
age after the second dose of an mRNA vaccine. There is a dedicated Comirnaty (Pfizer), Spikevax (Moderna) and
cardiac inflammation web page that provides information, guidance and detailed resources on these side effects.
The Therapeutic Goods Administration (TGA) details Australian cases of myocarditis and pericarditis associated with
mRNA vaccines in the COVID-19 weekly safety report.
Related resources:
Clinical guidance for COVID-19 vaccine providers
Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines
COVID-19 vaccination: summary for immunisation providers | 23 February 2022 2COVID-19 vaccine safety surveillance AusVaxSafety (as at 23 February 2022) AusVaxSafety is conducting comprehensive active safety monitoring of all COVID-19 vaccines being used in Australia. The latest safety surveillance data report on adverse events following COVID-19 vaccination for all participants, including Aboriginal and Torres Strait Islander people. Just over 6 million participants have responded to surveys, with 44.8% reporting an adverse event following COVID-19 vaccination. Most common adverse events include injection site pain, fatigue, headache and other expected side effects following immunisation. Related resource: AusVaxSafety COVID-19 vaccine safety surveillance Therapeutic Goods Administration The TGA is closely monitoring suspected adverse events following vaccination with COVID-19 vaccines in use in Australia. The latest weekly safety report of the TGA provides detailed information about the reported side effects for COVID-19 vaccines, total adverse event reports, reporting rates per 1000 doses by jurisdiction, and most commonly reported vaccine side effects. The most frequently reported suspected side effects continue to be events that were seen in the clinical trials and are commonly experienced with vaccines generally. Related resource: TGA COVID-19 vaccine safety weekly report Variants of concern The World Health Organization (WHO) is tracking SARS-CoV-2 variants Related resource: WHO Variants of concern COVID-19 vaccination: summary for immunisation providers | 23 February 2022 3
Vaccine ingredients
Vaxzevria (COVID- Comirnaty (Pfizer) – Comirnaty (Pfizer) – Spikevax (Moderna) NUVAXOVID COVID-19
19 Vaccine 12 years and older 5-11 years and older Red cap VACCINE (adjuvanted)
AstraZeneca) Purple cap Orange cap
Red cap
Ingredients • Histidine • ((4- • ((4- • Heptadecan-9-yl 8-[2- • Matrix-M adjuvant, which
(List of • Histidine hydroxybutyl)azanedi hydroxybutyl)azanedi hydroxyethyl-(6-oxo-6- contains:
excipients) hydrochloride yl)bis(hexane-6,1- yl)bis(hexane-6,1- undecoxyhexyl)amino]oc • Quillaja Saponaria
monohydrate\ diyl)bis(2- diyl)bis(2- tanoate saponins fraction A
• Sodium chloride hexyldecanoate) hexyldecanoate) • Cholesterol • Quillaja Saponaria
• Magnesium (ALC-0315) (ALC-0315) • Distearoylphosphatidylc saponins fraction C
chloride • 2-[(polyethylene • 2-[(polyethylene holine • cholesterol
hexahydrate glycol)-2000]-N,N- glycol)-2000]-N,N- • 1,2-dimyristoyl-rac- • phosphatidyl choline
• Disodium edetate ditetradecylacetamid ditetradecylacetamide glycero-3- • monobasic
(EDTA) e (ALC-0159) (ALC-0159) methoxypolyethylene potassium phosphate
• Sucrose • Distearoylphosphatid • Distearoylphosphatid glycol-2000 (PEG2000- • potassium chloride
• Ethanol absolute ylcholine (DSPC) ylcholine (DSPC) DMG) • Dibasic sodium
• Polysorbate 80 • Cholesterol • Cholesterol • Trometamol phosphate
• Water for injection • Potassium chloride • Trometamol • Trometamol heptahydrate
• Monobasic • Trometamol hydrochloride • Monobasic sodium
potassium phosphate hydrochloride • Acetic acid phosphate
• Sodium chloride • SucroseWater for • Sodium acetate monohydrate
• Dibasic sodium injections trihydrate • Sodium chloride
phosphate • Sucrose • Polysorbate 80
dihydrate4ehydrate • Water for injection • Sodium hydroxide (for
• Sucrose pH adjustment)
• Water for injections • Hydrochloric acid (for
pH adjustment)
• Water for injections
Related resource: COVID-19 vaccine product information
COVID-19 vaccination: summary for immunisation providers | 23 February 2022 4Answering patients’ questions and concerns about COVID-19 vaccines NCIRS COVID-19 vaccines: Frequently asked questions NCIRS COVID-19 and children: Frequently asked questions Decision aid: Should I get the COVID-19 vaccine? COVID-19 vaccines – Is it true? VaxFACTS Case numbers and statistics Coronavirus (COVID-19) case numbers and statistics Other resources Discussion guide for medical exemptions General COVID-19 vaccine exemptions fact sheet Specialist immunisation services Accessing the Australian Immunisation Register ASCIA Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement ASCIA Allergy and COVID-19 Vaccination - Guide for health professionals ASCIA Immunodeficiency, Autoimmunity and COVID-19 Vaccination - Guide for health professionals COVID-19 vaccines and cancer: Health professional guidance COVID-19 vaccination: summary for immunisation providers | 23 February 2022 5
You can also read
